Does Anthem Cover Wegovy? Prior Authorization Guide

When Does Anthem Cover Wegovy for Weight Loss

Anthem covers Wegovy for weight loss only when an employer plan includes an optional anti-obesity benefit rider and the patient satisfies clinical prior authorization rules. Anthem operates health plans across multiple states, offering both fully-insured group plans and administrative services for self-funded employer groups. In a self-funded plan, the employer pays member medical claims directly out of corporate accounts, giving that employer direct control over which prescription drug categories to include in its formulary.

Weight-loss medications represent an ongoing cost for benefit sponsors. To manage health plan premiums, many commercial employers exclude weight-loss drugs from their standard prescription benefit design. When an employer chooses that exclusion, Anthem automatically denies pharmacy claims for Wegovy, regardless of clinical need or a physician prescription.

State insurance regulations create further variation. Fully-insured plans in states such as California, New York, and Virginia operate under state-level benefit mandates that require coverage for certain metabolic therapies. Self-funded plans governed by federal regulations remain exempt from those state requirements. Checking your specific plan documents remains the only reliable method to confirm whether your policy includes weight-management coverage.

Wegovy vs Ozempic Indication Differences and Formulary Impact

Wegovy and Ozempic contain the identical active drug molecule, semaglutide, but Anthem evaluates them under separate coverage rules because the Food and Drug Administration (FDA) approved them for different medical indications. Novo Nordisk manufactures both brand-name products as pre-filled injection pens administered once weekly. The central difference between the two products involves their FDA-approved clinical indications and how health insurers categorize those indications.

The FDA approved Ozempic to lower blood sugar in adults with type 2 diabetes mellitus and to reduce major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. In contrast, the FDA approved Wegovy for chronic weight management in adults with obesity or overweight accompanied by at least one weight-related condition. Because commercial insurers view type 2 diabetes as a standard chronic disease, Anthem plans routinely cover Ozempic under established diabetes clinical criteria.

Anthem does not extend that same automatic coverage to Wegovy. When a clinician prescribes Wegovy for weight management, the claim routes to a separate benefit category that requires an employer-purchased rider. As explained in our guide on Anthem Ozempic coverage, prescribers who attempt to bypass this restriction by ordering Ozempic off-label for weight management encounter strict diabetes prior authorization audits. For patients evaluating different weight-management therapies, our Wegovy vs Zepbound comparison outlines how semaglutide compares to dual-incretin medications in clinical studies.

The Role of the Anthem Weight Loss Drug Rider

An Anthem weight loss drug rider is a supplemental benefit contract that an employer must purchase for commercial plans to pay for anti-obesity medications. Standard commercial health plans offered by Anthem exclude weight-loss drugs by default. Unless an employer chooses to add and fund this optional rider, the pharmacy benefit system rejects Wegovy claims as an excluded benefit category.

This contracting structure creates wide differences in coverage among Anthem members. One member working for a company that purchased the rider can receive coverage for Wegovy with a standard tier copayment. A second member with an Anthem card from an employer that opted out of the rider faces a complete denial at the pharmacy counter.

Plan funding structures explain much of this variation. Self-funded health plans operate under the Employee Retirement Income Security Act of 1974 (ERISA), a federal law that exempts them from state-level insurance mandates. Even in states that require commercial insurers to offer obesity treatment benefits, an ERISA-governed self-funded plan retains legal authority to exclude Wegovy entirely. Review our guide to Anthem pharmacy prior authorizations to understand how plan structures determine formulary access.

Anthem Wegovy Prior Authorization and Clinical Criteria

Anthem approves prior authorization for Wegovy only when medical records document that a patient satisfies specific Body Mass Index (BMI) thresholds and lifestyle modification criteria. Even when your plan includes an active weight-loss rider, approval requires clinical documentation from your doctor. CarelonRx reviews these submissions to verify that patients meet FDA label guidelines before releasing medication coverage.

To qualify for an initial approval under weight-management guidelines, medical records must establish one of two baseline criteria:

• A baseline Body Mass Index of 30 kg/m² or greater, meeting the clinical definition of obesity.
• A baseline Body Mass Index of 27 kg/m² or greater with at least one documented weight-related medical condition, such as high blood pressure, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.

Prescribers must also supply documentation demonstrating that the patient attempted a structured lifestyle program involving a reduced-calorie diet and regular exercise. Initial prior authorization approvals generally last between six and twelve months, depending on the specific Anthem plan contract.

Coverage renewal requires objective evidence of therapeutic benefit. Prescribers must submit follow-up chart notes showing that the patient achieved and maintained a weight reduction, typically set at a minimum of 5% of their starting baseline body weight. If a member does not achieve this benchmark during the initial authorization period, Anthem terminates coverage upon renewal review.

How CarelonRx Wegovy Coverage Requests Are Reviewed

CarelonRx serves as the pharmacy benefit manager (PBM) for Anthem and conducts all clinical prior authorization reviews for Wegovy prescriptions. CarelonRx is the in-house pharmacy organization operated by Anthem parent company Elevance Health, having operated under the name IngenioRx before a corporate rebranding in 2023. When your doctor sends a prescription for Wegovy to a pharmacy, CarelonRx receives and evaluates the claim.

The review starts with an automated check against your employer benefit structure. If your employer contract does not include the weight-loss rider, CarelonRx issues an immediate administrative rejection without assessing medical necessity. When the rider is active, the claim moves to clinical staff for prior authorization review.

The clinical review team evaluates medical records to confirm that your diagnosis, baseline BMI, and comorbidity documentation match policy criteria. Clinicians also check for safety contraindications, including any personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Submitting thorough clinical chart notes on the initial request helps prevent unnecessary administrative delays.

When Does Anthem Cover Wegovy for Cardiovascular Risk

Anthem plans can cover Wegovy to reduce major adverse cardiovascular events in adults with established cardiovascular disease who are overweight or obese. In March 2024, the Food and Drug Administration (FDA) approved Wegovy for this expanded cardiovascular indication, establishing a clinical pathway separate from chronic weight management alone. This approval provides an evidence-based mechanism for patients with pre-existing heart disease.

To qualify under the cardiovascular indication, medical documentation must confirm established atherosclerotic cardiovascular disease. Qualifying diagnoses include a documented history of heart attack, ischemic stroke, or symptomatic peripheral arterial disease. In addition to verified vascular disease, the patient must have an initial Body Mass Index of 27 kg/m² or higher.

This indication offers a secondary coverage route for patients whose employer plans exclude standard weight-loss medications. Because reducing major cardiovascular events treats serious vascular disease rather than weight alone, certain Anthem plans process these requests through medical necessity pathways rather than the optional weight-loss rider. Coverage terms under this indication vary by policy, so members should have their cardiologist or prescribing doctor verify exact CarelonRx criteria for cardiovascular event reduction.

Who Will Not Qualify for Anthem Wegovy Coverage

Anthem will not approve Wegovy for individuals whose plans exclude weight-loss riders and who lack diagnosed cardiovascular disease. Because weight-management coverage remains an optional employer add-on, many commercial members encounter plan-level exclusions that medical necessity appeals cannot overturn. When an employer contract explicitly excludes anti-obesity drugs, CarelonRx must enforce that policy decision.

Clinical criteria also prevent several patient populations from receiving Wegovy authorization:

• Individuals with a baseline Body Mass Index below 27 kg/m², or those with a BMI between 27 and 29.9 kg/m² without a qualifying weight-related health condition.
• Patients seeking medication for cosmetic weight loss or short-term body weight adjustments.
• Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Individuals currently prescribed another glucagon-like peptide-1 (GLP-1) receptor agonist, as combined incretin therapy is not approved.
• Individuals who are pregnant, planning to become pregnant, or breastfeeding.

Policy changes could shift these coverage boundaries in the future. If federal lawmakers pass legislation requiring commercial insurers to cover obesity medications as essential health benefits, Anthem would adjust its standard commercial formularies. Similarly, if Elevance Health moves Wegovy onto standard commercial tiers without requiring an employer rider, access would widen for members. Until such policy shifts occur, plan exclusions determine member eligibility.

Steps to Take If Anthem Denies Your Prior Authorization

If Anthem denies your prior authorization for Wegovy, review the written denial notice to determine whether the decision was administrative or clinical. An initial denial from CarelonRx does not mean your options are closed. Identifying the specific reason for rejection allows you and your doctor to take targeted action.

Follow these steps to address an Anthem coverage denial:

1. Obtain the official denial letter from CarelonRx to find the exact denial code, which indicates whether the claim failed due to a plan exclusion or missing clinical chart documentation.
2. Review your Summary of Benefits and Coverage (SBC) document through the Anthem member portal to confirm whether weight-loss medications appear as an excluded benefit category.
3. If CarelonRx denied coverage due to incomplete clinical records, ask your doctor to submit a formal appeal containing your baseline BMI measurements, comorbidity records, and diet trial notes.
4. If you have documented heart disease and your plan excludes weight-management drugs, ask your prescriber to evaluate submitting an appeal under the March 2024 cardiovascular risk reduction indication.
5. If your plan has a strict rider exclusion, contact your human resources department or benefits coordinator during open enrollment to request adding the weight-loss benefit rider to future contract years.

Confirm your plan's specific rider status and formulary tier with CarelonRx or your benefits coordinator before your doctor writes a prescription to determine whether does Anthem cover Wegovy under your current policy.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black

GE

View on Amazon →

Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass

Etekcity

View on Amazon →